Home | Business News | Browse by Publication | M | M2 Presswire

"Penny Stocks that Perform" picks are: Diagnostic Imaging International Corp. - DIIG - CTS Signs Daytime Coverage Contract!

Article Excerpt
M2 PRESSWIRE-20 April 2009-PennyPerformers.com: "Penny Stocks that Perform" picks are: Diagnostic Imaging International Corp. - DIIG - CTS Signs Daytime Coverage Contract!(C)1994-2009 M2 COMMUNICATIONS LTD

RDATE:20042009

Pennyperformers.com "Penny Stocks that Perform" picks are: Diagnostic Imaging International Corp. (OTCBB: DIIG), Forest Laboratories, Inc. (NYSE: FRX), GreenChek Technology Inc (OTCBB: GCHK), IntegraMed America, Inc. (NASDAQ: INMD), Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)...and Proudly Introducing Proprietary Push Technology (PPT).

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration.

http://newmediaadvisors.info/newmedia.swf

Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com

Apr 20, 2009 -- Diagnostic Imaging International Corp. (OTCBB: DIIG) announced today that its wholly owned subsidiary, Canadian Teleradiology Services ("CTS"), has signed a new contract to supply daytime service.

CTS recently signed an existing client Hospital for daytime coverage of teleradiology services. The hospital had been pleased with the dedicated rapid night and weekend service they had been receiving that they requested a new second contract with CTS to cover daytime services.

Until recently CTS had been exclusively focused on night time and weekend service as most hospitals use their resident radiologist for daytime service. The opportunity to service hospitals in the daytime and offer complete 24/7 service is an opportunity for rapid expansion for the Company.

"CTS is very pleased to once again meet the individual demands and challenges that many rural hospitals face", said Richard Jagodnik, CEO. "To offer this new service adds a new dimension and revenue stream to our business model that should increase our bottom line."

April 20, 2009, 2009 -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) announced today that Savella(TM) (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor approved for the management of fibromyalgia, will be shipped to wholesalers on April 24th and will be available at pharmacies beginning on April 28th. After Savella was approved by the U.S. Food and Drug Administration (FDA) on January 14, 2009, the companies submitted a minor post-approval cosmetic formulation change to the FDA which now has been approved.

About Savella

Savella was approved by the FDA on January 14, 2009 for the management of fibromyalgia, a chronic condition characterized by widespread pain and decreased physical function that afflicts as many as six million people in the United States. Savella is a dual-reuptake inhibitor that, in-vitro, preferentially blocks the reuptake of norepinephrine with higher potency than serotonin, two neurotransmitters thought to a play a central role in the symptoms of fibromyalgia. Savella will be marketed by Forest and its licensor, Cypress Bioscience. Pierre Fabre, who originally developed and sells milnacipran outside the U.S., licensed the rights for North America to Cypress Bioscience.

Important Safety Information

Savella is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), similar to some drugs used for the treatment of depression and other psychiatric disorders. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children,...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!